Scarica l'app Stockscreener
7.94
0.76%
0.06
Precedente Chiudi:
$7.88
Aprire:
$7.84
Volume 24 ore:
1.40M
Relative Volume:
0.79
Capitalizzazione di mercato:
$788.47M
Reddito:
$98.99M
Utile/perdita netta:
$-197.98M
Rapporto P/E:
-3.9666
EPS:
-2.0017
Flusso di cassa netto:
$-175.32M
1 W Prestazione:
-7.24%
1M Prestazione:
-14.25%
6M Prestazione:
-39.20%
1 anno Prestazione:
-55.84%
Intervallo 1D:
$7.67
$8.07
Intervallo di 1 settimana:
$7.49
$8.6646
Portata 52W:
$6.66
$18.63
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
7.94 | 788.47M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Northland Capital | Outperform |
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
(SPRY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc.SPRY - PR Newswire
What's Going on With ARS Pharma Stock Thursday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
ARS Pharmaceuticals appoints Donn Casale as CEO - The Globe and Mail
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirt - The National Law Review
ARS Pharmaceuticals: CEO Richard Lowenthal Will No Longer Serve as Employee and Officer, Effective July 6 - Moomoo
ARS Pharmaceuticals stock falls as CEO Lowenthal steps down By Investing.com - Investing.com South Africa
ARS Pharmaceuticals appoints new CEO - MSN
ARS Pharmaceuticals Announces CEO Succession - Investing News Network
ARS Pharmaceuticals Names Casale CEO, Succeeding Co-Founder Lowenthal - Moomoo
ARS Pharmaceuticals names Donn Casale as new CEO By Investing.com - Investing.com South Africa
ARS Pharmaceuticals names Donn Casale as new CEO - Investing.com
ARS Pharmaceuticals stock falls as CEO Lowenthal steps down - Investing.com
Donn Casale becomes ARS Pharmaceuticals (SPRY) CEO and joins board through 2029 - Stock Titan
ARS Pharmaceuticals, Inc. Announces CEO Changes - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
ARS Pharmaceuticals stock plunges 23% after Nef... - Pluang
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals, Inc. (SPRY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ARS Pharmaceuticals (SPRY) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (SPRY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceu - The National Law Review
SPRY Should I Buy - Intellectia AI
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ARS Pharmaceuticals (SPRY) President awarded 898,456 long-term stock options - Stock Titan
ARS Pharmaceuticals plunges 23% as Neffy fails to secure insurance coverage - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud - Business Wire
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
(SPRY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ARS Pharmaceuticals, Inc.(NasdaqGM: SPRY) dropped from Russell 2000 Defensive Index - marketscreener.com
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) - PR Newswire
Micron Stock And 2 Fast Growth Picks With Major Catalysts Ahead - Sahm
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices - Yahoo Finance
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index - marketscreener.com
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Levi & Korsinsky Announces Investigation of Securities Claims Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Price to earnings forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Price to earnings forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Price to sales forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.moomoo - Moomoo
Director Rajeev Dadoo granted 30,000 ARS Pharmaceuticals (SPRY) stock options - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dadoo Rajeev - Moomoo
Director at ARS Pharmaceuticals (SPRY) receives 30,000 stock options - Stock Titan
ARS Pharmaceuticals (SPRY) director option grant tied to OrbiMed - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kelly Michael - Moomoo
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):